Fortrea Holdings Inc
NASDAQ:FTRE
Intrinsic Value
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. [ Read More ]
The intrinsic value of one FTRE stock under the Base Case scenario is 38.41 USD. Compared to the current market price of 26.91 USD, Fortrea Holdings Inc is Undervalued by 30%.
Valuation Backtest
Fortrea Holdings Inc
Run backtest to discover the historical profit from buying and selling FTRE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Fortrea Holdings Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 108.6m |
Receivables | 1.1B |
Other Current Assets | 92.4m |
Non-Current Assets | 3.1B |
PP&E | 220.9m |
Intangibles | 2.8B |
Other Non-Current Assets | 82.7m |
Current Liabilities | 775.9m |
Accounts Payable | 132.8m |
Accrued Liabilities | 375.6m |
Other Current Liabilities | 267.5m |
Non-Current Liabilities | 1.8B |
Long-Term Debt | 1.6B |
Other Non-Current Liabilities | 276.6m |
Earnings Waterfall
Fortrea Holdings Inc
Revenue
|
3.1B
USD
|
Cost of Revenue
|
-2.6B
USD
|
Gross Profit
|
520.4m
USD
|
Operating Expenses
|
-433m
USD
|
Operating Income
|
87.4m
USD
|
Other Expenses
|
-90.8m
USD
|
Net Income
|
-3.4m
USD
|
Free Cash Flow Analysis
Fortrea Holdings Inc
FTRE Profitability Score
Profitability Due Diligence
Fortrea Holdings Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Fortrea Holdings Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
FTRE Solvency Score
Solvency Due Diligence
Fortrea Holdings Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Fortrea Holdings Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FTRE Price Targets Summary
Fortrea Holdings Inc
According to Wall Street analysts, the average 1-year price target for FTRE is 41.31 USD with a low forecast of 33.33 USD and a high forecast of 47.25 USD.
Ownership
FTRE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FTRE Price
Fortrea Holdings Inc
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -33% |
Market Capitalization | 2.4B USD |
Shares Outstanding | 87 333 300 |
Percentage of Shares Shorted | 10.68% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 19,000 full-time employees. The company went IPO on 2023-06-16. The firm is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.
Contact
IPO
Employees
Officers
The intrinsic value of one FTRE stock under the Base Case scenario is 38.41 USD.
Compared to the current market price of 26.91 USD, Fortrea Holdings Inc is Undervalued by 30%.